Technology evaluation: SB-485232, GlaxoSmithKline
Golab, J.; Stoklosa, T.
Current Opinion in Molecular Therapeutics 7(1): 85-93
2005
ISSN/ISBN: 1464-8431 PMID: 15732534 Document Number: 594417
GlaxoSmithKline (formerly SmithKline Beecham), under license from Hayashibara, is developing SB-485232, a recombinant human interleukin-18 cancer immunotherapy for the potential treatment of immunologically sensitive cancers, including melanoma and renal cell cancer. The compound is currently undergoing phase II clinical trials.